Vall d'Hebron Institute of Research (VHIR), a renowned medical research centre, and SYNLAB, a leader in medical diagnostic services, are pleased to announce an agreement whereby SYNLAB will help fund and advance research conducted at VHIR. The aim of this collaboration is to advance priority research projects that will have a significant impact on medical care and the quality of life of patients.

VHIR's research projects include the study of systemic autoimmune-based diseases. The collaboration between SYNLAB and VHIR will allow the promotion of research on these pathologies that especially affect women of childbearing age and, therefore, can also appear during pregnancy.
Specifically, the Systemic Diseases group at VHIR, led by Dr. Jaume Alijotas-Reig, investigates the identification of biomarkers for the diagnosis and prognosis of primary antiphospholipid syndrome, an autoimmune disorder in which the immune system attacks blood cells and the lining of blood vessels. In particular, this project focuses on the analysis of its obstetric variant, that is, the one that appears in pregnant women and is associated with various complications in gestation and puerperium. To this end, Dr. Alijotas-Reig and his group work in close collaboration with members of the Systemic Autoimmune Diseases Unit of the Vall d'Hebron University Hospital, a reference in Spain and Europe, of which he is a senior consultant.

According to VHIR's director, Dr. Begoña Benito: "This agreement represents a significant step in our efforts to remain a leader in medical research. We are grateful to SYNLAB for their support and commitment to our mission. Together, we will be able to conduct innovative research that will enable us to address today's medical challenges and improve the quality of life of patients".

SYNLAB, for its part, values highly this strategic partnership with one of the country's leading research centres, as it will provide it with a deeper insight into current and future medical challenges and strengthen its ability to provide cutting-edge diagnostic services. By joining forces with VHIR, the company is demonstrating its commitment to scientific excellence and its strong support for biomedical research.

The CEO of SYNLAB Spain, Mr. Albert Sumarroca, also expressed his satisfaction with this agreement, stating: "We are delighted to collaborate with VHIR on this important initiative. As a leader in medical diagnostic services, we recognise the importance of medical research to improve patient care and promote scientific advances. We are committed to providing our financial support and resources to advance cutting-edge research at Vall d'Hebron".

Both parties are excited about the opportunities this collaboration will bring and look forward to reaching new milestones in medical research. Together, SYNLAB and VHIR are committed to advancing science and improving people's health and well-being.